Week 4 notes 7 - TreatmentofRespiratoryInflammation...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Treatment of Respiratory Inflammation Leukotriene modifiers, corticosteroids and cromones are therapies used to reduce inflammation in the respiratory tract. In addition to reducing the number and activity of inflammatory cells, they can often enhance the effect of the bronchodilators and can be used concurrently. List of Available Leukotriene Modifiers Used in Respiratory Disorders zafirlukast (Accolate) montelukast (Singulair) Pharmacodynamics of the Leukotriene Modifiers Zafirlukast and montelukast are leukotriene antagonists, meaning they block various leukotriene receptors. Leukotrienes are a type of inflammatory biomediator in the lung and have been shown to play a significant role in asthma and allergy. Use of these modifier drugs may prevent leukotriene-induced inflammation. Pharmacokinetics of the Leukotriene Modifiers The leukotriene modifier drugs are administered orally. They are both metabolized in the liver; however, zafirlukast is largely excreted in the feces while montelukast is mainly excreted in the bile. Advantages of the Leukotriene Modifiers in Respiratory Disorders - Administered orally BID; convenient and infrequent dosing improves compliance - Long duration of action; 12-14 hrs - Can be used prophylactically in asthma - Acts synergistically with the other anti-asthmatic drugs, often allowing reduction in their doses (especially the steroids) - Useful in exercise-induced asthma Disadvantages of the Leukotriene Modifiers in Respiratory Disorders - Not effective as monotherapy; requires the presence of other anti-asthma medications to produce a desirable therapeutic response - Not useful in acute bronchospasm - May produce dry mouth and cough - Adverse effects include headache, dizziness, nausea, diarrhea, and abdominal pain - Zafirlukast is a hepatic enzyme inhibitor; it is capable of increasing the serum 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Treatment of Respiratory Inflammation concentrations of other drugs (pharmacokinetic potentiative drug-drug interaction) - Zafirlukast must be taken on an empty stomach
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 5

Week 4 notes 7 - TreatmentofRespiratoryInflammation...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online